Biotech Values

[DewDiligence]

>MNTA – why does everyone give these outlandish valuations to mnta because of its generic lovenox when arixtra will take business away from lovenox when they get their label expanded?<

That’s an easy one: Lovenox sells $4.5B a year and is growing strongly (#msg-28903176), while Arixtra is a commercial dog that sells a couple of hundred million a year.

Yes, an expanded label for Arixtra will help to some degree, but it won’t increase sales twenty-fold. Many docs are wary of Arixtra because they think the therapeutic window is too narrow.

p.s. The Arixtra news you just posted is referenced from my index file on anticoagulants in #msg-28838788.